BCBSM pulling back on GLP-1 coverage
US$ 23.15
glp-1/glucagon dual receptor agonist Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review Polyagonists Enable Increasingly Effective Treatment
Description
Understanding how long GLP-1 medications take to start working helps set realistic expectations for when these blood markers will shift
Most type 2 diabetes patients tolerate semaglutide well, but those on insulin or sulfonylureas need dose adjustments to prevent dangerously low blood sugar
However, the impact of GLP-1 on mood and wakefulness in humans is unknown [21]
doi: 10.1007/s00125-011-2174-9
Yet cardiomyocytes, the main muscle cells of the heart, and hepatocytes in the liver do not appear to express GLP-1 or GIP receptors in significant amounts
10.1021/acsnano.4c11172
